Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a $103 price target. The positive stance aligns with a Consensus Strong Buy rating from 13 Wall Street analysts, comprising 12 Buys and 1 Hold.

The average price target on Ultragenyx Pharmaceutical is $76.83, implying 111.65% upside potential from current levels of $36.30. On November 21, Cantor Fitzgerald reaffirmed its Overweight rating and $105 price target on Ultragenyx Pharmaceutical following third-quarter 2025 results and recent financial actions. Ultragenyx, which focuses on rare and ultra-rare genetic diseases, announced on November 4 the sale of an additional portion of future royalty interest in Crysvita, one of its key commercial products. Cantor noted that while the deal strengthens liquidity, it does not alter the firm’s overall valuation view of the company.

Ultragenyx reported Q3 revenue of $160 million, below the consensus of $167 million, and EPS of -1.81 versus the expected -1.23. Despite the shortfalls, the company confirmed its full-year revenue guidance of $640 to $670 million. To further support its financial position, Ultragenyx sold 25% of its North American Crysvita economics, receiving $400 million upfront from OMERS. Cantor Fitzgerald adjusted its model to account for these moves but maintained confidence in Ultragenyx’s long-term growth, highlighting the company’s strategic focus on rare disease therapies and its ability to use Crysvita royalties to advance the pipeline and create shareholder value.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company focused on developing and commercializing treatments for severe, debilitating, rare, and ultra-rare genetic diseases, using modalities like biologics, gene therapies, and ASOs to address high unmet medical needs.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.